Retinal Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Online Providers is the fastest growing sector, North America is the largest market

The Global Retinal Biologics Market is projected to expand from USD 16.18 billion in 2025 to USD 21.18 billion by 2031, reflecting a compound annual growth rate of 4.59%. These biological treatments, primarily vascular endothelial growth factor inhibitors delivered via intravitreal injection, are essential for managing progressive eye conditions such as age-related macular degeneration and diabetic macular edema. The sector's growth is largely driven by an aging global population and rising rates of diabetes, creating a critical need for long-term therapies to prevent vision loss from retinal complications.

High treatment costs and the discomfort of frequent eye injections pose significant hurdles to market development, often resulting in patient noncompliance. Despite these challenges, the demand for effective therapies persists due to the growing global burden of ocular diseases. According to the International Agency for the Prevention of Blindness in 2025, the number of people suffering from sight loss is expected to reach 1.8 billion by 2050. This forecast highlights the urgent requirement for scalable therapeutic solutions within the retinal biologics landscape.

Market Drivers

The rising global incidence of diabetes and its associated complications serves as a fundamental catalyst for the retinal biologics industry. As systemic metabolic disorders become more common, the consequent increase in diabetic macular edema and diabetic retinopathy requires continuous pharmacologic treatment to avert permanent blindness. This demographic trend creates essential demand for intravitreal therapies, with the International Diabetes Federation’s 2025 'IDF Diabetes Atlas 11th Edition' reporting that 11.1% of the global adult population now lives with diabetes. This vast patient pool necessitates sustained volume growth in the market as healthcare providers rely on standard anti-VEGF treatments to manage these chronic threats to vision.

Concurrently, the competitive landscape is being transformed by advancements in novel gene therapies and long-acting biologics that address the heavy burden of frequent treatments. Patients and physicians are increasingly adopting next-generation bispecific antibodies and high-dose formulations that permit longer intervals between doses, thereby enhancing compliance and outcomes. For instance, Roche’s '2024 Annual Report' from January 2025 noted that the bispecific antibody Vabysmo achieved full-year sales of CHF 3.9 billion, while Regeneron’s 'Third Quarter 2024 Financial Results' in October 2024 reported Eylea HD generated $392 million in U.S. net sales for that quarter alone. These figures confirm the sector's decisive shift toward durable therapeutics that offer reduced injection frequency.

Market Challenges

The major obstacle constraining the Global Retinal Biologics Market is the high cost of medication coupled with the substantial burden of frequent intravitreal injections. Because these biological agents require repeated administration to preserve sight, they impose a compounding financial and logistical weight on patients and healthcare infrastructures alike. Consequently, many individuals face treatment fatigue or unmanageable out-of-pocket costs, resulting in poor adherence, missed appointments, or total therapy cessation. This pattern of noncompliance directly diminishes the addressable patient base and restricts the long-term revenue opportunities for approved branded biologics.

Furthermore, the economic strain of these recurring expenses compels clinical practices to modify prescribing habits, often negatively impacting market value. When financial safety nets are exhausted, physicians are frequently forced to transition patients from premium, first-line branded therapies to less expensive, off-label alternatives to maintain some level of care. According to the American Society of Retina Specialists in 2025, 93 percent of surveyed retina specialists indicated they switched patients to lower-cost options following the depletion of charitable copay assistance funds. This significant migration away from premium treatments erodes the market share of approved biologics and underscores the vulnerability of growth that relies on subsidized patient access.

Market Trends

The rapid commercialization of anti-VEGF biosimilars is fundamentally reshaping market dynamics by challenging the dominance of legacy brands and introducing cost-efficient competition. As patents for key reference biologics expire, major pharmaceutical companies are actively launching biosimilar alternatives that provide comparable clinical efficacy at lower prices, thereby widening patient access and driving price reductions across the industry. This trend is illustrated by the swift uptake of newly approved aflibercept biosimilars; for example, Amgen’s 'Q1 2025 Earnings Call' in May 2025 reported that their biosimilar Pavblu achieved $99 million in quarterly sales, signaling strong adoption by payers and retinal specialists.

Simultaneously, the rise of complement inhibitors for Geographic Atrophy marks a pivotal expansion from managing wet age-related macular degeneration to treating previously untreatable dry forms of the condition. This novel therapeutic class targets the complement cascade to retard lesion progression, effectively unlocking a significant market segment defined by high unmet medical needs. The successful adoption of these pioneering therapies highlights the critical demand for treatments that preserve vision in advanced non-neovascular disease. According to Apellis Pharmaceuticals’ 'Q3 2025 Financial Results' from October 2025, the complement inhibitor Syfovre recorded net product revenue of $150.9 million for the quarter, validating the commercial potential of therapeutics addressing this broad patient population.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Biocon Limited
• Biogen Inc.
• Coherus BioSciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Outlook Therapeutics, Inc.
• Regeneron Pharmaceuticals, Inc.

Report Scope

In this report, the Global Retinal Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Biologics Market, by Drug Class:

• VEGF-A Antagonist
• Others

Retinal Biologics Market, by Indication:

• Macular Degeneration
• Diabetic Retinopathy
• Others

Retinal Biologics Market, by Distribution Channel:

• Hospital Pharmacies
• Online Providers
• Drug Stores
• Retail Pharmacies

Retinal Biologics Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Biologics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.